BR112012027543A8 - formulações de quinonas para tratamento de doenças oftálmicas - Google Patents

formulações de quinonas para tratamento de doenças oftálmicas Download PDF

Info

Publication number
BR112012027543A8
BR112012027543A8 BR112012027543A BR112012027543A BR112012027543A8 BR 112012027543 A8 BR112012027543 A8 BR 112012027543A8 BR 112012027543 A BR112012027543 A BR 112012027543A BR 112012027543 A BR112012027543 A BR 112012027543A BR 112012027543 A8 BR112012027543 A8 BR 112012027543A8
Authority
BR
Brazil
Prior art keywords
quinone
formulations
quinones
formulation
formula
Prior art date
Application number
BR112012027543A
Other languages
English (en)
Other versions
BR112012027543A2 (pt
Inventor
M Miller Guy
Original Assignee
Bioelectron Tech Corp
Edison Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Tech Corp, Edison Pharmaceuticals Inc filed Critical Bioelectron Tech Corp
Publication of BR112012027543A2 publication Critical patent/BR112012027543A2/pt
Publication of BR112012027543A8 publication Critical patent/BR112012027543A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulações de quinonas para o tratamento de doenças oftálmicas. uma formulação compreendendo uma quantidade oftalmicamente efetiva de uma ou mais quinonas de fórmula i. uso de uma formulação compreendendo uma ou mais quinonas de fórmula i para a prevenção, redução, melhora ou tratamento de distúrbios oftálmicos que são associados com um distúrbio de trauma ou neurodegenerativo também é discutido. um processo de tratamento ou controle de sintomas oculares associados com doenças neurodegenerativas ou trauma com uma formulação compreendendo uma ou mais quinonas de fórmula i também é discutido. um processo de tratamento ou controle de sintomas associados com miopatias mitocondriais com uma formulação compreendendo uma ou mais quinonas de fórmula i também é discutido.
BR112012027543A 2010-04-27 2011-04-26 formulações de quinonas para tratamento de doenças oftálmicas BR112012027543A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32854610P 2010-04-27 2010-04-27
US39369310P 2010-10-15 2010-10-15
PCT/US2011/033983 WO2011137126A1 (en) 2010-04-27 2011-04-26 Formulations of quinones for the treatment of ophthalmic diseases

Publications (2)

Publication Number Publication Date
BR112012027543A2 BR112012027543A2 (pt) 2019-05-28
BR112012027543A8 true BR112012027543A8 (pt) 2019-12-03

Family

ID=44861894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027543A BR112012027543A8 (pt) 2010-04-27 2011-04-26 formulações de quinonas para tratamento de doenças oftálmicas

Country Status (13)

Country Link
US (2) US20130109759A1 (pt)
EP (1) EP2563352A4 (pt)
JP (2) JP5902673B2 (pt)
CN (2) CN102985083A (pt)
AU (1) AU2011245384C1 (pt)
BR (1) BR112012027543A8 (pt)
CA (1) CA2797581A1 (pt)
EA (1) EA201201465A1 (pt)
MX (1) MX337594B (pt)
MY (1) MY183449A (pt)
SG (2) SG185046A1 (pt)
WO (1) WO2011137126A1 (pt)
ZA (1) ZA201208535B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
MX359292B (es) 2005-06-01 2018-09-24 Bioelectron Tech Corp Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia.
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
WO2009089224A1 (en) 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
EP2262508B1 (en) 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
PT2963006T (pt) 2008-10-28 2018-12-14 Bioelectron Tech Corp Composição contendo alfa-tocotrienol quinona e seus intermediários
MX336800B (es) 2009-04-28 2016-02-02 Edison Pharmaceuticals Inc Tratamiento de neuropatia optica hereditaria de leber y atrofia optica dominante con tocotrienol quinonas.
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
EP2555765A4 (en) * 2010-04-06 2013-08-14 Edison Pharmaceuticals Inc TREATMENT OF ATAXIE TÉLANGIECTASIE
JP5902673B2 (ja) * 2010-04-27 2016-04-13 エジソン ファーマシューティカルズ， インコーポレイテッド 眼疾患の処置のためのキノンの製剤
EP2720689A4 (en) 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CA2883879A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2971252A1 (en) 2014-12-16 2016-06-23 Bioelectron Technology Corporation Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2019070917A1 (en) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359292B (es) * 2005-06-01 2018-09-24 Bioelectron Tech Corp Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia.
BRPI0616041A2 (pt) * 2005-09-16 2011-06-07 Allergan Inc composições e métodos para o transporte intra-ocular de agentes terapêuticos
CA2635280C (en) * 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
LT3827815T (lt) * 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
EP2555765A4 (en) * 2010-04-06 2013-08-14 Edison Pharmaceuticals Inc TREATMENT OF ATAXIE TÉLANGIECTASIE
JP5902673B2 (ja) * 2010-04-27 2016-04-13 エジソン ファーマシューティカルズ， インコーポレイテッド 眼疾患の処置のためのキノンの製剤

Also Published As

Publication number Publication date
US20130109759A1 (en) 2013-05-02
EA201201465A1 (ru) 2013-04-30
JP6266674B2 (ja) 2018-01-24
AU2011245384C1 (en) 2016-09-01
EP2563352A4 (en) 2013-11-13
EP2563352A1 (en) 2013-03-06
SG10201801321XA (en) 2018-04-27
AU2011245384B2 (en) 2016-02-18
JP5902673B2 (ja) 2016-04-13
ZA201208535B (en) 2016-06-29
CN102985083A (zh) 2013-03-20
CA2797581A1 (en) 2011-11-03
JP2016106144A (ja) 2016-06-16
MX2012012518A (es) 2012-12-17
MX337594B (es) 2016-03-11
SG185046A1 (en) 2012-12-28
JP2013525443A (ja) 2013-06-20
BR112012027543A2 (pt) 2019-05-28
AU2011245384A1 (en) 2012-12-06
CN105147651A (zh) 2015-12-16
WO2011137126A1 (en) 2011-11-03
MY183449A (en) 2021-02-18
US20170354618A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
BR112012027543A2 (pt) formulações de quinonas para tratamento de doenças oftálmicas
MX2011011310A (es) Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas.
BR112015020050A2 (pt) material óptico, composto para material óptico e sua utilização
BR112014026703A2 (pt) inibidores de dna-pk
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015003742A2 (pt) sistema de montagem de componente de descarga
MY165124A (en) Semifluorinated alkane compositions
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112015010059A2 (pt) terapia adjuvante com inibidor da quinase da família tec
DOP2013000300A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BR112017007025A2 (pt) sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
BR112014017902A2 (pt) Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2563 DE 2020-02-18

B350 Update of information on the portal [chapter 15.35 patent gazette]